<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="446">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05155345</url>
  </required_header>
  <id_info>
    <org_study_id>GA43191</org_study_id>
    <nct_id>NCT05155345</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered Mosunetuzumab to Participants With Systemic Lupus Erythematosus</brief_title>
  <official_title>A Phase Ib, Multicenter, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered Mosunetuzumab to Participants With Systemic Lupus Erythematosus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of&#xD;
      mosunetuzumab in participants with systemic lupus erythematosus (SLE).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">December 16, 2021</start_date>
  <completion_date type="Anticipated">July 21, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 21, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of participants with adverse events (AEs)</measure>
    <time_frame>For a minimum of 12 months after mosunetuzumab dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum concentration of mosunetuzumab</measure>
    <time_frame>Through Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peripheral B-cell count</measure>
    <time_frame>Through Month 12, then every 6 months thereafter</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of B-cell depletion</measure>
    <time_frame>Through Month 12, then every 6 months thereafter</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in anti-drug antibodies (ADAs)</measure>
    <time_frame>Through Month 12</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Systemic Lupus Erythematosus</condition>
  <arm_group>
    <arm_group_label>Non-fractionated/Dose-finding</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single dose of mosunetuzumab.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fractionated/Dose-escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a fractionated (divided) dose of mosunetuzumab on Days 1 and 8.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mosunetuzumab</intervention_name>
    <description>Participants will receive subcutaneous (SC) mosunetuzumab on either Day 1 or on Days 1 and 8.</description>
    <arm_group_label>Fractionated/Dose-escalation</arm_group_label>
    <arm_group_label>Non-fractionated/Dose-finding</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tocilizumab</intervention_name>
    <description>Participants will receive intravenous (IV) tocilizumab as needed to manage adverse reactions.</description>
    <arm_group_label>Fractionated/Dose-escalation</arm_group_label>
    <arm_group_label>Non-fractionated/Dose-finding</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of SLE according to the 2019 European League Against Rheumatism/American&#xD;
             College of Rheumatology Classification Criteria at least 12 weeks or more prior to&#xD;
             screening&#xD;
&#xD;
          -  Presence of one or more of the following SLE autoantibodies documented within the 12&#xD;
             months prior to screening or during screening: positive ANA (greater than or equal to&#xD;
             1:160); anti dsDNA above the upper limit of normal (ULN); anti-Sm above the ULN&#xD;
&#xD;
          -  Active SLE disease, as demonstrated by a SLEDAI-2K total score of greater than or&#xD;
             equal to 4 at screening&#xD;
&#xD;
          -  Current receipt of one or more of the following classes of standard therapies for the&#xD;
             treatment of SLE at stable doses: oral corticosteroids (OCSs), antimalarial agents,&#xD;
             conventional immunosuppressants&#xD;
&#xD;
          -  For women of childbearing potential: agreement to remain abstinent (refrain from&#xD;
             heterosexual intercourse) or use contraception as defined by the protocol&#xD;
&#xD;
          -  For men on mycophenolate mofetil (MMF): With a female partner of childbearing&#xD;
             potential, men who are not surgically sterile must remain abstinent (refrain from&#xD;
             heterosexual intercourse) or use contraception as defined by the protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or breastfeeding, or intending to become pregnant during the study or within&#xD;
             3 months after the final dose of mosunetuzumab and 3 months after the final dose of&#xD;
             tocilizumab&#xD;
&#xD;
          -  Active severe or unstable lupus-associated neuropsychiatric disease that is likely to&#xD;
             require treatment with protocol-prohibited therapies&#xD;
&#xD;
          -  Active overlap syndrome with mixed connective tissue disease or systemic sclerosis&#xD;
             within 12 months prior to screening or during screening&#xD;
&#xD;
          -  Catastrophic or severe antiphospholipid syndrome within 12 months prior to screening&#xD;
             or during screening&#xD;
&#xD;
          -  Presence of significant lupus-associated renal disease and/or renal impairment that is&#xD;
             likely to require treatment with protocol-prohibited therapies&#xD;
&#xD;
          -  Peripheral CD19+ B-cell count &lt; 25 cells/uL&#xD;
&#xD;
          -  Receipt of an investigational therapy within 30 days or 5 drug-elimination half-lives&#xD;
             (whichever is longer) prior to initiation of study treatment and during the study&#xD;
&#xD;
          -  Receipt of any of the following excluded therapies: any anti-CD19 or anti-CD20 therapy&#xD;
             such as blinatumomab, obinutuzumab, rituxumab, ocrelizumab, or ofatumumab less than 12&#xD;
             months prior to screening or during screening; inhibitors of JAK, Bruton tyrosine&#xD;
             kinase, or tyrosine kinase 2, including baricitinib, tofacitinib, upadacitinib,&#xD;
             filgotinib, ibrutinib, or fenebrutinib, or any investigational agent within 30 days&#xD;
             prior to screening or during screening; tacrolimus, ciclosporin, or voclosporin within&#xD;
             30 day prior to screening or during screening; cyclophosphamide or a biologic therapy&#xD;
             such as but not limited to belimumab, ustekinumab, anifrolumab, secukinumab, or&#xD;
             atacicept during 2 months prior to screening or during screening; any live or&#xD;
             attenuated vaccine during 28 days prior to screening or during screening&#xD;
&#xD;
          -  High risk for any clinically significant bleeding or any condition requiring&#xD;
             plasmapheresis, IV immunoglobulin, or acute blood product transfusions&#xD;
&#xD;
          -  Significant or uncontrolled medical disease that would preclude participation&#xD;
&#xD;
          -  HIV infection, acute or chronic hepatitis B virus (HBV), acute or chronic hepatitis C&#xD;
             (HCV) infection, tuberculosis (TB) infection, known or suspected chronic active&#xD;
             Epstein-Barr virus (EBV) infection, or cytomegalovirus (CMV) infection&#xD;
&#xD;
          -  Active infection of any kind, excluding fungal infection of the nail beds&#xD;
&#xD;
          -  Any major episode of infection that fulfills any of the following criteria: requires&#xD;
             hospitalization during 8 weeks prior to screening or during screening; requires&#xD;
             treatment with IV antibiotics (or anti-infective medications) during 8 weeks prior to&#xD;
             screening or during screening; requires treatment with oral antibiotics (or&#xD;
             anti-infective medications) during 2 weeks prior to screening or during screening&#xD;
&#xD;
          -  History of serious recurrent or chronic infection&#xD;
&#xD;
          -  History of progressive multifocal leukoencephalopathy (PML)&#xD;
&#xD;
          -  History of cancer, including solid tumors, hematological malignancies, and carcinoma&#xD;
             in situ, within the past 5 years&#xD;
&#xD;
          -  Major surgery requiring hospitalization during 4 weeks prior to screening or during&#xD;
             screening or any planned surgery or procedure requiring hospitalization during 12&#xD;
             weeks following study drug administration&#xD;
&#xD;
          -  Current alcohol or drug abuse or history of alcohol or drug abuse within 12 months&#xD;
             prior to screening or during screening&#xD;
&#xD;
          -  Intolerance or contraindication to study therapies including history of severe&#xD;
             allergic or anaphylactic reactions to monoclonal antibodies or known hypersensitivity&#xD;
             to any component of mosunetuzumab injection&#xD;
&#xD;
          -  Positive serum human chorionic gonadotropin measures at screening&#xD;
&#xD;
          -  Any of the following laboratory parameters: aspartate transaminase (AST) or alanine&#xD;
             transaminase (ALT) &gt; 2.5 x upper limit of normal (ULN); total bilirubin &gt; 1.5 x ULN;&#xD;
             absolute neutrophil count (ANC) &lt; 2.0 x 10^9/L (&lt; 2000/mm^3); platelet count &lt; 100 x&#xD;
             10^9/L (100,000 mm^3); hemoglobin &lt; 100 g/L (10 g/dL); estimated glomerular filtration&#xD;
             rate (eGFR) &lt; 30 ml/min/1.73 m^2 calculated according to the Chronic Kidney Disease&#xD;
             Epidemiology Collaboration equation; positive serum human chorionic gonadotropin&#xD;
             measured at screening&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reference Study ID Number: GA43191 https://forpatients.roche.com/</last_name>
    <phone>888-662-6728</phone>
    <email>global-roche-genentech-trials@gene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Pinnacle Research Group; Llc, Central</name>
      <address>
        <city>Anniston</city>
        <state>Alabama</state>
        <zip>36207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>December 10, 2021</study_first_submitted>
  <study_first_submitted_qc>December 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 13, 2021</study_first_posted>
  <last_update_submitted>December 10, 2021</last_update_submitted>
  <last_update_submitted_qc>December 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

